Earley W, et al. - In this double-blind placebo-controlled study, researchers randomly assigned adult participants (18–65 years old) who met DSM-5 criteria for bipolar I disorder and a current depressive episode to receive placebo (N=158) or cariprazine at 1.5 mg/day (N=157) or 3.0 mg/day (N=165) to assess the efficacy, safety, and tolerability of cariprazine in bipolar I depression. As per outcomes, adults with bipolar I depression generally well-tolerated cariprazine, at both 1.5 mg/day and 3.0 mg/day, in addition to indicating its efficacy and relative safety at both doses in reducing depressive symptoms.